Whitfield Advises Vertex on $10 Billion Acquisition of Crinetics
Overview
Vertex agreed to acquire Crinetics for approximately $10 billion of equity value, according to the source announcement about endocrine-disease medicines.
Offer economics
The proposed cash price was $85 per share, equivalent to approximately $8.8 billion after estimated acquired cash. Both boards approved the agreement unanimously.
Product portfolio
The source identifies paltusotine, marketed as PALSONIFY, and development candidate atumelnant among Crinetics' assets. These descriptions concern the announced acquisition, not treatment recommendations.
Timing and advisers
Completion was expected in the third quarter of 2026. Graham Robinson, Laura Knoll and Merric Kaufman are among the corporate advisers credited.
